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Intercellular Trafficking and Protein
Delivery by a Herpesvirus Structural Protein
Gillian Elliott and Peter O'Hare envelope, which is termed the tegument (Dargan, 1986).
In this paper we show that one of these proteins, theMarie Curie Research Institute
The Chart structural protein VP22 (Elliott and Meredith, 1992), ex-
hibits a combination of features that distinguishes it asOxted, Surrey RH8 0TL
United Kingdom a protein with novel trafficking properties. Like a small
number of unusual proteins, such as interleukin 1b (Ru-
bartelli et al., 1990), the HIV-1 Tat protein (Ensoli et al.,
1993), and the fibroblast growth factors (FGFs) (JacksonSummary
et al., 1992), VP22 is exported from cells in which it is
synthesized, in spite of lacking a signal sequence, byWe show that the HSV-1 structural protein VP22 has
a Golgi-independent mechanism termed nonclassicalthe remarkable property of intercellular transport,
secretion (Kuchler, 1993). VP22 is unique, however, inwhich is so efficient that following expression in a
its ability to reenter surrounding cells with such a highsubpopulation the protein spreads to every cell in a
level of efficiency that, after endogenous synthesis in amonolayer, where it concentrates in the nucleus and
small subpopulation of cells, the protein formed gradi-binds chromatin. VP22 movement was observed both
ents in surrounding recipient cells and could spreadafter delivery of DNA by transfection or microinjection
to virtually every cell in a transfected monolayer. VP22and during virus infection. Moreover, we demonstrate
movement was also observed after delivery of DNA bythat VP22 trafficking occurs via a nonclassical Golgi-
microinjection and after infection with a disabled non-independent mechanism. Sensitivity to cytochalasin D
replicating virus. Moreover, in recipient cells VP22 wastreatment suggests that VP22 utilizes a novel traffick-
directed to the nucleus, despite lacking a nuclear local-ing pathway that involves the actin cytoskeleton. In
ization sequence, where it bound to chromatin and seg-addition, we demonstrate intercellular transport of a
regated to daughter cells. We show that uptake of VP22VP22 fusion protein after endogenous synthesis or ex-
does not involve the standard route of endocytosis, butogenous application, indicating that VP22 may have
appears to involve a novel pathway that is cytochalasinpotential in the field of protein delivery.
D sensitive and therefore would seem to requirean intact
actin cytoskeleton.Finally, we show that by modificationIntroduction
of VP22, both a peptide and a 27 kDa protein could be
delivered to all cells in a monolayer after endogenousThe trafficking of proteins within the eukaryotic cell is
expression, the first time such delivery has been docu-prerequisite for the ordered delivery of individual cellular
mented. Taken together, these features suggest thatcomponents to their appropriate compartments. The
VP22 will be both an extremely useful tool for analyzinghighly regulated intracellular pathways that utilize the
nonclassical transport within the eukaryotic cell, and abudding and fusion of membrane-bound vesicles for
potential vector for protein delivery.such activities as transport within the cell, secretion out
of the cell, and uptake into the cell via endocytosis are
now very broadly understood (Rothman, 1994; Rothman Results
and Wieland, 1996). Nascent proteins destined for traf-
ficking are targeted cotranslationally to the lumen of the Heterogeneity in VP22 Cellular Localization
As part of our program to characterize the structuralendoplasmic reticulum (ER) by an N-terminal hydropho-
bic signal sequence. Vesicles containing these proteins tegument proteins of HSV-1, we initiated a detailed anal-
ysis of one of the major proteins of this compartment,then bud from the ER and are conveyed to the Golgi
apparatus where they are sorted to their ultimate desti- the 38 kDa protein VP22 (Figure 1A). To examine its
pattern of independent subcellular localization, COS-1nation of either internal organelles or the plasma mem-
brane. On the inward path, endocytosis involves the cells were transfected with a VP22 expression vector
and analyzed by indirect immunofluorescence using theinternalization of extracellular molecules through the in-
vagination and subsequent pinching of vesicles from the monoclonal antibody P43 (Elliott and Meredith, 1992).
Consistent with our previous results (Elliott et al., 1995),cell surface, which are then conveyed to the endosomal
compartment. P43 does not cross-react with untransfected cells (Fig-
ure 1B, mock), while the predominant pattern observedTogether with many other aspects of cell biology, the
field of protein trafficking has been significantly en- in transfected cells was that of nuclear staining, fre-
quently with enrichment around the nuclear rim (Figurehanced by studies carried out on eukaryotic viruses.
We have been interested in protein trafficking in herpes 1B, WT VP22, left-hand panel). In a number of cells,
however, VP22 was present in a distinctive cytoplasmicsimplex virus type 1 (HSV-1) infected cells and in the
features involved in targeting and selective incorpora- filamentous pattern (Figure 1B, WT VP22, right-hand
panel). We further noted that these two patterns weretion into different virion compartments during virus as-
sembly. In particular, we have been investigating the always detected in adjacent cells, with one cell con-
taining cytoplasmic VP22 surrounded by several cellsproperties and subcellular localization of a group of
structural proteins that make up the poorly understood containing nuclear VP22 (Figure 1C, WT VP22). Compari-
son of the cellular localization of a VP22 mutant thatregion of the virion located between the capsid and the
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Figure 2. VP22 Spreads between Cells during Transient Expression
(A) Cell-staining patternobserved at low magnification with antibody
AGV30 for untransfected COS-1 cells (mock) and pGE109
transfected cells (WT VP22).
Figure 1. Cellular Localization of HSV-1 VP22 during Transient Ex- (B) Cell-staining patterns observed with antibody AGV30 using 10-
pression fold less DNA for transfection than in (A) for both pGE109 (WT VP22)
(A) Coding sequence of VP22, the product of the HSV-1 UL49 gene, and the C-terminal deletion mutant (D267). In (A) and (B) images
showing the truncation point for the D267 mutant. were collected using a 103 objective.
(B) Cell-staining patterns observed with antibody P43 for un- (C) COS-1 cells were microinjected with a mixture of plasmids
transfected COS-1 cells (mock) and pGE109 transfectedCOS-1 cells pGE109 and pBAG, incubated for 24 hr, and double immunofluores-
(WT VP22). cence carried out with the anti-b-galactosidase antibody (b-Gal),
(C) Comparison of VP22 localization patterns observed with P43 in and AGV30 (VP22). The same field is shown in both panels and the
cells transfected with pGE109 (WT VP22), and the C-terminal dele- injected cell is arrowed.
tion mutant (D267). (D) COS-1 cells transfected with pGE109 were mixed with un-
transfected BHK-21 cells at a ratio of 1:20, and 20 hr later double
immunofluorescence carried out with the anti±T antigen antibody
pAB419 (T Ag) and AGV30 (VP22). The same field is shown in bothlacks the C-terminal 34 residues (D267, Figure 1A) dem-
panels with the COS-1 cell expressing VP22 arrowed.onstrated that this striking characteristic of VP22 local-
ization in cell clusters was specific to the full-length
protein. While D267 was synthesized in transfected cells
that the C-terminal deletion mutant localized only in theat similar levels to WT VP22, as judged by Western blot
cell of expression indicated that a determinant at the(e.g. see Figure 4B), the mutant VP22 protein was only
extreme C-terminus of VP22 may be essential for itsfound in the cytoplasmic filamentous pattern, and was
transport function.not detected in the nuclei of surrounding cells (Figure
1C, D267). Furthermore, the numbers of cells containing
VP22 within the cytoplasm were approximately the same VP22 Can Spread into the Nuclei of All Cells
in a Tissue Culture Monolayerfor the mutant and WT proteins. This specific relation-
ship of a central cell with cytoplasmic VP22 immediately To investigate further the movement of VP22 between
cells, we utilized an independent polyclonal antibody tosurrounded in a nonrandom mannerby cells with nuclear
VP22, together with the phenotype of a mutant with only VP22 (AGV30) todefine the proportion of cells containing
VP22 following transfection. As expected, this antibodythe cytoplasmic pattern suggested that VP22 exhibited
an unusual property whereby the protein localized to did not cross-react with untransfected COS-1 cells (Fig-
ure 2A, mock). Strikingly, however, immunofluorescencethe cytoplasm of the cell in which it was initially ex-
pressed and was transported to adjacent cells where it of transfected cells examined at low magnification
clearly showed that VP22 was present within every cellaccumulated in the nuclei. Moreover, the observation
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of the monolayer (Figure 2A, WT VP22), a property not
observed with any other test protein we have compared.
Within these monolayers, an approximate 10% subpop-
ulation containedVP22 in its bright cytoplasmic staining,
while the remainder contained lower intensity nuclear
VP22. To analyze the efficiency of VP22 spreading, we
used 10-fold less plasmid DNA such that a field con-
taining only a few expressing cells could be observed
at low magnification. The D267 mutant was examined
in parallel, and typical results are shown in Figure 2B.
The D267 mutant VP22 protein was only detectable in
the two transfected cells within the field (Figure 2B,
D267). In contrast, transfection of WT VP22 under the
same conditions resulted in a gradient of VP22 emanat-
ing from a single transfected cell in the center of the field
into a halo of surrounding cells, which had a diameter of
up to 16 cells (Figure 2B, WT VP22). This powerful image Figure 3. VP22 Is Transported during Virus Infection
both demonstrates that in the course of transfection (A) and (B) COS-1 cells were infected with the gH2 mutant of HSV-1
at a multiplicity of 0.1, and double immunofluorescence carried outone VP22-expressing cell synthesizes protein that is
30 hr later using anti-b-galactosidase antibody (b-Gal), and AGV30destined to reach at least 200 other cell nuclei, and
(VP22). Images taken at high (A) and low(B) magnification are shown,provides the explanation for the ability of VP22 to reach
and the same field stained for both proteins is shown in each case.
every cell in a transfected monolayer from a subset of
expressing cells (Figure 2A).
VP22 Is Transported between CellsTo prove that VP22 possesses the ability to move
during Virus Infectionbetween cells, we used microinjection as an alternative
The role of VP22 during HSV-1 infection is as yet unclear,technique of introducing plasmid DNA into cells. The
but if the protein moves between cells during the courseplasmid encoding VP22 was injected into the nuclei of
of a virus infection, it is likely that this property will beindividual COS-1 cells, togetherwith an expression plas-
relevant to some aspect of the virus replication cycle.mid for b-galactosidase to confirm and mark the single
In determining if VP22 exhibits intercellular movementinjected cells. Typical results are shown in Figure 2C.
during infection, it was necessary to ensure that, withinThe injected cells were easily distinguishable by their
any candidate VP22 recipient cell, VP22 was not beingreaction with an anti-b-gal antibody (arrowed in Figure
synthesized de novo but had originated from a separate2C, b-gal), which did not react with any of the sur-
virus-infected cell. We therefore investigated the spreadrounding cells. The injected cell also contained VP22
of VP22 in cells infected with a disabled HSV-1 mutantwithin its cytoplasm (arrowed in Figure 2C, VP22), but
in which the gene for the glycoprotein gH, known toin striking contrast to b-galactosidase, VP22 was pres-
be essential for virus entry into the cell (Gompels andent not only in the injected cell but also in the nuclei
Minson, 1986; Fuller et al., 1989), had been replacedof all the surrounding cells (Figure 2C, VP22). These
by the gene encoding b-galactosidase (Forrester et al.,experiments confirm the results obtained by DNA trans-
1992). When the mutant virus is grown on a gH-express-fection and prove conclusively that VP22 has the ability
ing cell line, infectivity is retained due to complementa-to spread from the original cell of expression into neigh-
tion by the endogenous gH protein that is incorporatedboring cells in a manner so efficient that it is detectable
into virions. However, when this complemented virus isby immunofluorescence.
used to infect a noncomplementing cell line, the virusThe experiments described so far were all carried out
can only initiate the original round of infection, and se-in COS-1 cells, but transfection of other cell-types, such
creted progeny virus particles cannot enter cells to initi-as BHK-21, Vero, or HeLa, also yielded the same results
ate a second round of infection. Thus, in normal cells(data not shown), demonstrating that VP22 movement
infected with this mutant, viral protein synthesis andis not specific to COS-1 cells. Moreover, we were able
assembly are limited to the primary infected cell, andto demonstrate intertypic cell spreading of VP22 by con-
any movement of VP22 observed in these cells must beducting the following experiment: COS-1 cells trans-
due to a mechanism other than uptake of infectiousfected with the VP22 expression vector were trypsinized
virus. A monolayer of 5 3 105 COS-1 cells was infected24 hr after transfection and mixed at a ratio of 1:20 with
with complemented gH2 virus at a mutiplicity such thattrypsinized nontransfected BHK-21 cells. The mixed cell
one in ten cells would be infected. Thirty hours later thepopulation was then plated and incubated for a further
cells were fixed and stained for both b-galactosidase24 hr. The COS-1 cells in this mixed monolayer were
(as a means of identifying infected cells) and VP22. Theeasily identified by staining for large T antigen (arrowed
infected cells stained intensely for b-galactosidase (Fig-in Figure 2D, T Ag). The same field stained for VP22
ure 3A, b-gal) and other viral proteins (data not shown).showed that VP22 synthesized in the original transfected
The VP22 staining in the infected cells was also intense,COS-1 cell (arrowed in Figure 2D, VP22) moved into the
but unlike b-galactosidase, VP22 was also detectablenuclei of surrounding BHK-21 cells (Figure 2D, VP22).
in the nuclei of all the uninfected cells (Figure 3A, VP22).No T antigen was observed in the BHK cells. Thus, an
This phenomenon was clearly demonstrated when theadditional feature of VP22 is that the protein can spread
between different cell-types. cells were examined at low magnification (Figure 3B),
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Figure 4. Transport of VP22 Occurs via a Nonclassical Mechanism
A) VP22 movement does not require functional Golgi transport. Vero cells transfected with pGE109 were incubated for 18 hr, Brefeldin A
added (2.5 mg/ml), and incubated for a further 22 hr in the presence of the inhibitor. Samples were taken at 18 hr (prior to addition of Brefeldin
A), 19 hr (1 hr after addition of Brefeldin A) and 40 hr, and double immunofluorescence carried out with AGV30 (VP22) and the anti-g-adaptin
monoclonal antibody (g-adaptin). The bottom two panels show COS-1 cells transfected with a gL expression vector, incubated in either the
absence or presence of Brefeldin A (2.5 mg/ml) as described for the top three panels, and stained for both g-adaptin and gL.
(B) Exogenous VP22 is taken up by cells. The left-hand panel shows a Western blot of cell-free extracts prepared from pGE109 (WT) and
D267 transfected COS-1 cells (D267), reacted with antibody AGV 30. Equal amounts of these extracts were added to the medium covering
5 3 105 COS-1 cells on coverslips. The cells were fixed 1 hr later and stained with the antibody AGV30. Examples are shown of both cell-
surface staining and permeabilized intracellular staining.
(C) Uptake of VP22 does not involve classical endocytosis. COS-1 cells were incubated for 15 min at 48C, and either a VP22-containing extract
(WT VP22), or Texas red±conjugated transferrin (Transferrin) added to the medium. The cells were maintained at 48C for 1 hr and fixed for
immunofluorescence. Both VP22 and Texas red-transferrin were also added to cells at 378C in parallel experiments. Samples of COS-1 cells
exposed to the WT-VP22 extract at both 48C and 378C were also used to prepare nuclear extracts, which were analyzed by Western blotting
using antibody AGV30 (left-hand panel).
where it can be seen that, while only z10% of the cells transfected Vero cells with the VP22 expression vector
and added Brefeldin A 18 hr later, at a time when VP22had been infected, VP22 was present within every cell
in the monolayer.This confirms that VP22 has the capac- had not yet left the original cells of expression (Figure
ity to spread between cells during infection. 4A, top panel, VP22). As a control for Golgi disruption,
the cellswere also stained for a Golgi marker, namely the
cellular protein g-adaptin (Robinson and Kries, 1992), aVP22 Movement Does Not Involve the Golgi
component of nonclathrin-coated vesicles that concen-Apparatus or Classical Endocytosis
trates in the Golgi (Figure 4A, top panel, g-adaptin). TheAnalysis of the VP22 open reading frame (Figure 1A)
action of Brefeldin A was almost immediate, as shownrevealed that it does not possess a hydrophobic
by the diffuse cytoplasmic staining of g-adaptin 1 hrN-terminal signal sequence and therefore was unlikely
after addition of the drug (Figure 4A, second panel,to be transported through the classical ER/Golgi route.
g-adaptin). However, after a further 20 hr exposure toTo investigate the role of the Golgi in VP22 transport
the drug, and with the Golgi still disrupted (Figure 4A,we used the drug Brefeldin A, which is known to disrupt
third panel, g-adaptin), VP22 had moved from the cellthe Golgi apparatus and inhibit classical vesicle-medi-
ated secretion (Lippincott Schwartz et al., 1990). We of synthesis into the nuclei of surrounding cells (Figure
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4A, third panel, VP22). As an additional control to the VP22 Movement between Cells Involves
the Actin Cytoskeletong-adaptin localization, we transfected cells with a vector
The fact that a protein enters a cell and trafficks effi-expressing the HSV-1 glycoprotein gL, which contains
ciently and rapidly to the nucleus, without using thea signal sequence for Golgi targetting (Hutchinson et
endocytotic pathway, suggests that it may utilize anal., 1992). Following transfection, cells were treated with
alternative connection between the cell surface and theBrefeldin A as before and stained for g-adaptin and gL
nucleus, rather than simply diffusing through the cell.(Figure 4A, bottom two panels). In untreated cells gL
The cytoskeleton of the cell could provide one suchwas localized in the Golgi in a manner similar to
pathway, with a combination of microtubules, intermedi-g-adaptin. After exposure to Brefeldin A, however, gL
ate filaments, and actin microfilaments forming a com-was relocalized throughout the cytoplasm of expressing
plex network of interconnected filaments running fromcells, confirming that treatment with the drug blocked
the cell surface through to the nuclear membrane. More-the trafficking of a signal sequence±containing protein.
over, the filamentous pattern of VP22 localization ob-These results, together with the Brefeldin A resistance
served in VP22-expressing cells suggested that it mayof VP22 transport, indicate that VP22 does not require
have the potential to interact with one or more of thean intact Golgi for transportation between cells and,
components of the cytoskeleton. Thus, we investigatedconsistent with its lack of a signal sequence, is likely to
the role of the individual componentsof the cytoskeletonbe secreted by a nonclassical mechanism.
in the VP22 import assay. First, to determine if the micro-Our results indicated that VP22 was either exported
tubule network was involved in VP22 trafficking, we uti-
from one cell into the medium from where it was taken up
lized the microtubule depolymerizing drug nocodazole.
by surrounding cells, or that it moved across intercellular
In theabsence of nocodazole treatment, themicrotubule
contacts. To examine the ability of VP22 to be imported
network was intact within the cell (Figure 5A, a-tubulin
from the medium, a soluble high-salt extract made from staining, 2 noc), and VP22 was imported into the nu-
VP22-expressing cells was added to the medium of un- cleus as described before (Figure 5A, VP22, 2 noc.).
transfected cells. Under these conditions VP22 was im- Pretreatment of cells with nocodazole prior to addition
ported and localized to the nucleus rapidly and effi- of the VP22 extract to the extracellular medium, resulted
ciently (Figure 4B, WT VP22, permeabilized sample), in the depolymerization of the microtubule network (Fig-
with VP22 detectable in the nuclei of cells within 5 min ure 5A, a-tubulin staining, 1 noc). VP22 was still im-
after addition to the medium. Moreover, the VP22 dele- ported efficiently, however, into the nuclei of these cells
tion mutant D267, while present in the soluble extract (Figure 5A, VP22 1 noc), indicating that intact microtu-
in equivalent amounts to full-length VP22 (Figure 4B, bules are not required for VP22 import.
left-hand panel), was never detected intracellularly (Fig- We next utilized the drug cytochalasin D to target the
ure 4B, D267, permeabilized sample). Staining of non- microfilament network within the cell. Pretreatment of
permeabilized cells demonstrated WT VP22 on the sur- cells with this microfilament-disrupting drug, prior to
face of cells, while the D267 protein could not be addition of the VP22-containing extract, resulted in a
detected (Figure 4B, cell-surface samples), implicating very different pattern of VP22 localization within the cell.
the C-terminal 34 residues in VP22 attachment to cells. While a proportion of VP22 was taken up and targeted
to the nucleus (Figure 5B, 1 cyto D permeabilized sam-We next addressed the mechanism of VP22 uptake
ple), the level of import was less than that observed inby cells. The standard route of entry for proteins into
untreated cells (Figure 5B, 2 cyto D). Furthermore, incells is receptor-mediated endocytosis, where proteins
cytochalasin D±treated cells VP22 localized around thebind to specific receptors on the cell-surface, and these
cell surface in large aggregates (Figure 5B, 1 cyto D,ligand/receptor complexes are internalized in clathrin-
permeabilized and cell-surface staining, cf. Figure 4C),coated membrane vesicles. It was therefore of interest
implying that cytochalasin D treatment had dramaticallyto determine if VP22 was imported by classical endocy-
altered the cell-surface binding sites of VP22.tosis by testing its sensitivity to incubation at 48C, a
To investigate further this proposal, we examined thetreatment well established to inhibit endocytosis (Pas-
effect of cytochalasin D treatment on VP22 transporttan and Willingham, 1981). As a control, we tested import
following endogenous synthesis during transfection.of Texas red±conjugated transferrin that is imported via
COS-1 cells were treated with cytochalasin D 8 hr after
the transferrin receptor and classical receptor-mediated
transfection, at a time when VP22 had not yet moved
endocytosis. As expected, transferrin was taken up by
from the original cell of expression. Twelve hours later
cells at 378C into vesicles located within the cytoplasm
the cells were fixed and assessed for VP22 movement
(Figure 4C, transferrin at 378C). At 48C, endocytosis of between cells. In untreated cells, VP22 had already
the transferrin was completely inhibited, and the protein moved into all the surrounding nuclei from the express-
exhibited a complete qualitatively distinct pattern, re- ing cell (Figure 5C, 2 cyto D). In the cells treated with
maining bound to its receptor on the cell surface (Figure cytochalasin D, however, there was no evidence for
4C, transferrin at 48C). In contrast, import of VP22 at 48C VP22 movement from the original expressing cells (Fig-
was little altered in comparison to that detected at 378C ure 5C, 1 cyto D). A series of control experiments dem-
(Figure 4C, WT VP22, compare 378C and 48C), a result onstrated that treatment with cytochalasin D had no
confirmed by Western blotting of nuclear extracts made effect on the level of VP22 within the cells or its integrity
from cells treated in the same manner (Figure 4C, left- (Figure 5D), confirming that the lack of VP22 movement
hand panel). These results suggest that internalization after treatment with the drug was not due to a reduced
of VP22 is energy-independent and occurs via a route level of synthesis or degradation of the protein. More-
over, cytochalasin D±treated cells were able to importother than normal endocytosis.
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Figure 5. A Role for the Cell Cytoskeleton in VP22 Uptake
(A) Prior to addition of a VP22-containing extract, COS-1 cells were incubated for 30 min in the absence (2 noc) or presence (1 noc) of 10
mg/ml nocodazole. Following addition of the extract, the cells were maintained in these conditions for 1 hr, and then fixed and stained with
both AGV30 (VP22), and the anti-a-tubulin antibody (a-tubulin).
(B) COS-1 cells were incubated for 15 min either in the absence (2 cyto D) or presence (1 cyto D) of the drug cytochalasin D (1 mM). A VP22-
containing extract was then added, and incubated in the same conditions for a further hour, whereupon the cells were fixed and stained with
AGV30. Examples are shown for both internal staining (Permeabilized) and cell-surface staining (Cell-surface) in the cytochalasin D-treated
cells.
(C) COS-1 cells transfected with pGE109 were incubated for 8 hr, and then cytochalasin D (1 mM) added to the medium. The cells were
incubated for a further 18 hr in the presence of the drug before being fixed and stained with AGV30 (1 cyto D). Cells treated in an identical
manner, but in the absence of cytochalasin D treatment, are also shown (2 cyto D). COS-1 cells incubated in cytochalasin D for 18 hr were
also exposed to Texas red-transferrin (Transferrin) for 1 hr, and examined for uptake.
(D) COS-1 cells treated as described in (C) were solubilized and analyzed by Western blotting with antibody AGV30.
Texas red±conjugated transferrin as efficiently as un- Delivery of Heterologous Polypeptides by VP22
These remarkable properties of potent transport andtreated cells (Figure 5C, Transferrin), indicating that
cytochalasin D had not caused an obvious pleiotropic nuclear targeting suggested that VP22 may represent a
realistic polypeptide delivery system. To investigate theeffect on the cells. These results demonstrate that
the actin microfilament network is involved in VP22 potential of VP22 to transport additional residues be-
tween cells, a vector containing the VP22 open readingtransport.
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intact, with an efficiency similar to that of WT, such that
the peptide tag could be detected within every cell in
the monolayer. It is also noteworthy that the fusion pro-
tein had an identical pattern of localization to WT VP22,
exhibiting efficient nuclear targeting.
We also tested the ability of VP22 to import this 12-
residue peptide by exogenous delivery. An import assay
was carried out as described above, using a soluble
extract from cells expressing the VP22-peptide fusion
protein. The efficiency of import of the fusion protein
was identical to that of WT VP22 (data not shown), sug-
gesting that the additional peptide did not interfere with
VP22 uptake. Taken together, these results demonstrate
that VP22 can efficiently deliver heterologous peptides
into cells either after endogenous synthesis and trans-
port, or by application to the medium and uptake.
Based on these results, we investigated further the
potential for delivering much larger intact reading
frames. VP22 was fused at its C-terminus to the coding
sequence of the 27 kDa jellyfish green fluorescent pro-
tein (GFP) (Chalfie et al., 1994) to produce a fusion pro-
tein of around 65 kDa. When this fusion protein was
expressed in COS-1 cells, it was synthesized intact,
as demonstrated by Western blotting with the antibody
anti-rGFP (Figure 6B). The subcellular localizations of
parental GFP and the 22±GFP fusion protein were then
determined using the anti-rGFP antibody. GFP ex-
pressed in COS-1 cells exhibited a diffuse cytoplasmic
and nuclear localization (Figure 6C), and was only de-
tectable in the original cell of expression. However, fu-
sion of GFP to the VP22 reading frame dramatically
altered the localization of GFP in the expressing cell
from its diffuse pattern to the filamentous cytoplasmic
pattern observed previously for VP22 (Figure 6D, top
panel). Moreover, the VP22-GFP fusion protein had
clearly moved into the surrounding untransfected cells
where, like WT VP22, the fusion protein was located in
the nucleus of the cell. This transported protein wasFigure 6. VP22 as a Delivery Vehicle for Heterologous Polypeptides
detected by antibodies to both the VP22 and the GFP(A) COS-1 cells were transfected with the plasmid UL49ep, which
elements of the fusion protein, confirming that the pro-expresses a VP22-peptide fusion protein. Forty hours after transfec-
tion the cells were fixed and stained with antibody AGV30. tein was intact. Furthermore, direct GFP fluorescence
(B) COS-1 cells were transfected with either plasmid pEGFP, which of the VP22 fusion was also detectable in the nuclei of
expresses the GFP protein, or pGE150, which expresses a VP22- the same field of cells (Figure 6D, lower panel). Thus,
GFP fusion. The cells were harvested 40 hr after transfection and VP22 has the capacity to deliver a 27 kDa protein into the
analyzed by Western blotting using the anti-rGFP antibody.
nuclei of adjacent cells following endogenous synthesis.(C) COS-1 cells transfected with pEGFP were fixed after 40 hr, and
In spite of the clearly efficient targeting of VP22 toimmunofluorescence carried out with anti-rGFP.
(D) COS-1 cells transfected with pGE150 were fixed after 40 hr, and the nuclei of recipient cells, there is no recognizable
analyzed by immunofluorescence with anti-rGFP (IF) and by direct consensus nuclear localization signal within the VP22
GFP fluorescence (FL). Both panels show the same field. sequence, although it does contain many basic residues
(E) Live cell fluorescence of COS-1 cells expressing 22-GFP. This (Figure 1A). While examining the nuclear localization of
example shows a cell going through mitosis.
VP22 under high magnification, we noted that in a pro-(F) COS-1 cells transfected with pGE109 were double labeled with
portion of cells it was present in a pattern similar to thatantibody P43 (VP22) and propidium iodide (DNA). Cells at the mitotic
of mitotic chromatin (eg. Figure 2C, VP22, bottom left-stages of prophase and prometaphase are shown, with the same
field shown in each panel. hand corner of microinjected cell). We therefore per-
formed dual staining of cells for both VP22 and DNA.
The results revealed that cells at all stages of mitosis
frame fused at its C-terminus to a 12-residue peptide, could be detected with VP22 localized around the con-
i.e., plasmidUL49ep (Leslie et al., 1996), was transfected densed chromosomes (Figure 6F, examples shown of
into COS-1 cells, and analyzed by immunofluorescence. prophase and prometaphase). Moreover, binding to
Staining with the antibody AGV30, which is specific to chromatin at all stages of mitosis was also observed
the N-terminus of VP22 (Figure 6A), or an antibody di- for the VP22±peptide fusion (data not shown) and the
rected against the C-terminus peptide (data not shown), VP22±GFP fusion (e.g. Figure 6E). Thus, VP22 is capable
of binding either directly or indirectly to chromatin, anrevealed that this fusion protein was indeed transported
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interaction that may help explain its efficient localization et al., 1996). In addition, one other example, the anten-
napedia homeodomain, has been reported to be takento the nucleus. Chromatin binding and segregation to
daughter cells are not altered by the addition of a large up by cells after exogenous supply (Joliot et al., 1991;
Derossi et al., 1994). Unlike VP22, however, only a subre-polypeptide to the C-terminus of VP22.
gion of the intact antennapedia protein is taken up by
cells, and there is no evidence that the protein is se-Discussion
creted after endogenous synthesis, suggesting that nei-
ther export nor import are features of the intact protein.In this paper we demonstrate that the HSV-1 structural
protein VP22 exhibits a combination of properties that The cellular mechanisms involved in release and up-
take of such proteins are not yet understood. Unlikedistinguish it as an extremely unusual protein. VP22 ex-
hibits the remarkable ability to spread between cells so VP22, interleukin 1b is found within membrane-bound
vesicles within the cytoplasm (Rubartelli et al., 1990). Itefficiently that after synthesis in only a small proportion
of cells the protein accumulates within every cell in a has been suggested that these vesicles represent recy-
cling endosomes and that release of interleukin 1b frommonolayer. VP22 moves from the cell in which it is syn-
thesized, and where it localizes largely in the cytoplasm, human monocytes may involve its sequestration by the
endosomal pathway; for although resistant to Golgi dis-to adjacent cells where it is imported and targeted to
the nucleus. This movement establishes gradients of ruption, treatments known to interfere with the endoso-
mal compartment inhibit its release (Rubartelli et al.,VP22 extending outward from the initially expressing
cell. Moreover, VP22 movement occurs not only when 1990). With regard to uptake, exogenous FGFs and Tat
have been shown to enter cells via receptor-mediatedthe protein is expressed individually, but also during
virus infection, implying that the property is biologically endocytosis (Mann and Frankel, 1991; Cao et al., 1993),
such that they become internalized and enter the incom-relevant. Neither VP22 export nor VP22 import involve
the classical routes of vesicular trafficking, but appear ing endosomal pathway. In contrast, we have shown
that VP22 does not enter cells through endocytosis, butto involve a novel microfilament-dependent route. Sig-
nificantly, we have shown that peptides and proteins of utilizes a novel pathway of entry that appears to involve
the actin cytoskeleton. Moreover, we have identified aup to 27 kDa can be delivered to cells as VP22 fusion
proteins by either endogenous synthesis or after appli- determinant at the extreme C-terminus of VP22 that is
absolutely essential for cell binding and entry, indicatingcation to the culture medium.
that this region is involved in the interaction between
VP22 and its cellular receptor. Because of the require-Mechanisms of Protein Trafficking
Most proteins that are exported from the cell possess ment for actin in VP22 uptake, we postulate that its
receptor may be one of the cell-surface proteins thatsignal sequences and are secreted via the Golgi appara-
tus. By contrast, a small group of proteins, which, like make contact either directly or indirectly with actin mi-
crofilaments. A precedent for such an interaction existsVP22, lack signal sequences, has been reported to be
transported by unknown Golgi-independent mecha- in the recently demonstrated association between the
internalin protein of L. monocytogenes, a bacterium thatnisms, including interleukin 1b, the FGFs, and HIV-1
Tat (Kuchler, 1993; Rubartelli and Sitia, 1995). However, utilizes actin to move through the cell, and its receptor,
i.e., the cell±cell adhesion molecule E-cadherin (Men-thorough analyses of the literature concerning such non-
classical pathways reveal that there are significant dif- gaud et al., 1996). Our results on the sensitivity of VP22
transport to cytochalasin D treatment cannot distinguishferences between these proteins and VP22. For exam-
ple, interleukin 1b is only secreted by specialized cells between the alternative situations of both export and
import being inhibited, or only import being inhibited.and then only in response to stimulation. Little or no
secretion was observed in, e.g., COS cells without the Thus, formally the possibility exists that the export path-
way involves an actin-independent mechanism.addition of a conventional leader sequence (Rubartelli
et al., 1990; Krasney and Young, 1992). Likewise, it has
been shown that the FGFs remain intracellular when
VP22 and Virus Replicationexpressed in tissue culture cells (Cao and Pettersson,
Our evidence that movement of VP22 occurs during1990), while their fate following cellular uptake remains
infection raises the possibility that this function is partcontroversial (Baldin et al., 1990; Cao et al., 1993). Al-
of the normal viral activity of the protein. VP22 is knownthough the 87-residue Tat protein has been reported to
to be modified by phosphorylation and nucleotidylationhave unusual transport properties (Helland et al., 1991;
in the infected cell (Elliott and Meredith, 1992; BlahoEnsoli et al., 1993), in our hands spread of the protein
et al., 1994), although neither the relevance of thesebetween cells was generally restricted to the nearest
modifications nor the function of VP22 within the infec-neighbors of the initial Tat-expressing cell. Moreover,
tious cycle are as yet understood. While current resultsafter exogenous supply, Tat was localized specifically
from our attempts to isolate a viral mutant in VP22 implyto the cytoplasm, in spite of possessing a well-defined
that it maybe essential, demonstrating that the transportnuclear localization signal (data not shown). Transacti-
role per se is essential will require separation of trans-vation by Tat under these conditions has been docu-
port determinants from other possible functional deter-mented as being extremely weak (Ensoli et al., 1993)
minants. Although we do not yet understand the preciseand may therefore be due to either only a very few
role of VP22 transport, it is tempting to speculate thatmolecules of the protein reaching the nucleus, or activa-
during the course of infection VP22, which is first detect-tion via an indirect cytosolic pathway such as the re-
cently documented Tat activation of NF-kB (DeMarchi able at around 4 hr after infection, would move between
Intercellular Spread of a Viral Protein
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Experimental Procedurescells at times prior to the production of infectious virions.
Once in the nuclei of the neighboring cells, VP22 could
Cells and Virusesact by some unknown mechanism to facilitate the ensu-
COS-1, Vero, and Hela cells were all maintained in Dulbecco's modi-
ing infection. This mechanism could take the form of fied minimal essential medium containing 10% newborn calf serum.
alteration of the nuclear architecture, interference with BHK-21 cells were maintained in Glasgow modified minimal essen-
tial medium containing 10% newborn calf serum and 10% tryptosethe cell-cycle, or activation/downregulation of cellular
phosphate broth. The HSV-1 disabled gH2 virus strain utilized ingenes. These novel results demonstrating a protein gra-
this study was kindly provided by T. Minson. Infections with thisdient after HSV infection may contribute to an under-
virus were carried out at a multiplicity of 0.1, using a virus stockstanding of mechanisms involved in virus pathogenesis,
that had been propagated on a complementing gH-expressing cell
and may expand the cellular mechanisms whereby sig- line. Following 1 hr adsorption, the medium was replaced with Dul-
naling gradients, e.g. in development processes, are becco's minimal essential medium containing 2% calf serum, and
infection allowed to progress for 30 hr prior to fixation.established.
VP22 in Gene Therapy Plasmids
Many of the properties we have described for VP22 The eukaryotic expression vector pGE109 contains the VP22 open
make it an attractive candidate for a novel cellular deliv- reading frame under the control of the human cytomegalovirus IE
promoter, and has been described previously (Elliott and Meredith,ery system. Notably, the protein can enter cells either
1992). The expression vectors for the C-terminal deletion mutant ofwhen synthesized endogenously or when supplied ex-
VP22, plasmid D267, and the VP22-peptide fusion protein, pUL49epogenously, making it appropriate for a variety of thera-
(Leslie et al., 1996), were generous gifts from J. McLauchlan. The
peutic applications. While several proteins have been HSV-1 glycoprotein L expression vector was kindly provided by T.
proposed as vehicles for exogenous delivery, and, for Minson. The expression vector for b-galactosidase, pBAG, has been
example, Tat has been successfully used to import described previously (Price et al., 1987). The GFPexpression vector,
pEGFPN1 was obtained from Cambridge Biosciences. Plasmidattached proteins from the medium (Fawell et al., 1994),
pGE150 was constructed by inserting the BamH1 fragment fromVP22 appears to be novel in possessing unusually po-
pUL49ep, containing the entire VP22 open reading frame, into thetent delivery properties following endogenous synthe-
BamH1 site of pEGFPN1, resulting in a fusion between VP22 and
sis. Moreover, fusion of a 27 kDa protein to the C-termi- GFP.
nus of VP22 allowed that peptide to be delivered to cells
either by endogenous or exogenous supply, confirming
Antibodies and Reagentsthat VP22 has thecapacity toact as a vehicle for delivery.
The monoclonal anti-VP22 antibody P43 and the polyclonal anti-In addition, endogenous synthesis following microinjec-
gL antibody were kindly provided by D. Meredith and T. Minson,
tion, a process easily envisaged as a mechanism of respectively. The polyclonal antibody AGV30 was raised against a
delivery in vivo, resulted in the spread of VP22 as effec- GST-VP22 fusion protein. Its specificity was tested by Western blot-
tively as that seen during transfection, where VP22 syn- ting prior to use in this study. Monoclonal anti-T antigen pAB419
has been described previously (Harlow et al., 1981). Monoclonalthesized in one cell can reach up to 200 other cells.
antibodies to g-adaptin and a-tubulin were obtained from Sigma,Import of the protein is rapid and efficient, resulting in
and the monoclonal antibody to b-galactosidase was obtained fromthe delivery of VP22 to the nucleus. Neither the nuclear
Promega. The polyclonal anti-rGFP antibody was obtained from
targeting norchromatin binding is alteredby theaddition Cambridge Biosciences.
of a peptide or even a 27 kDa protein, suggesting that Brefeldin A (used at 2.5 mg/ml), nocodazole (used at 10 mg/ml),
VP22 has the potential to deliver factors specifically to and cytochalasin D (used at 1 mM) were obtained from Sigma. Texas
Red-conjugated transferrin (used at 50 mg/ml) was obtained fromthe nuclear compartment. In addition, VP22 movement
Molecular Probes.and import do not appear to be cell-type specific, with
the protein capable of moving in every cell-type so far
tested. Moreover, our results demonstrate that VP22 Transfection and Microinjection
Cells for immunofluorescence were plated into 6-well trays (6 3 35can move between different cell-types. An additional
mm) at a density of 2 3 105 cells per well, containing one coverslipadvantage of VP22 import is that normal endocytosis is
per well. They were transfected with a DNA mix consisting of 200not involved, and VP22 can gain rapid access to the
ng of expression plasmid made up to 2 mg with pUC19 DNA, usingcell. Other potential exogenous delivery systems, such
the calcium phosphate precipitation technique modified with BES
as Tat (Mann and Frankel, 1991) or bacterial toxins [N,N-bis(2-hydroxyl)-2-aminoethanesulfonic acid]-buffered saline in
(Stenmark et al., 1991; Prior et al., 1992), are taken up place of HEPES-buffered saline.
by endocytosis, which may result in the retention of To carry out a cell import assay, cell-free extracts were made
from 106 transfected COS-1 cells in a buffer consisting of 10 mMthese proteins for lengthy periods in endosomal vesi-
HEPES (pH 7.9), 400 mM NaCl, 0.1 mM EDTA, 0.5 mM DTT and 5%cles, and thus excluded from the intracellular environ-
glycerol. Half of the extract was then added to the medium coveringment, or more drastically delivered to lysosomes and
5 3 105 cells in a 35 mm well, containing a single coverslip.
degraded. Finally, the conflicting requirements in viral- Nuclear fractions were prepared from cells exposed to these solu-
mediated delivery, to limit replication and pathogenesis ble extracts by washing cells twice in cold PBS, followed by incuba-
while introducing the protein of interest efficiently to tion on ice for 10 min in 10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl2,
10 mM KCl, 0.5 mM and 1% Triton X-100. Nuclei were pelleted bymany cells, areof relevance to theconsideration of deliv-
a brief centrifugation, washed once in the same buffer, and lysedery protocols. A debilitated virus such as the gH2 virus
in SDS-PAGE loading buffer.used here would provide an excellent biological system
For microinjection, cells were plated into 6-well trays at a density
for delivering a vector into a limited number of cells of 5 3 105 cells per well, containing one coverslip per well. Cells
from which VP22, or fusion proteins of VP22, would were injected with a solution containing 100 ng/ml plasmid DNA
then spread out into many cells in a tissue, ensuring in PBS, using a Carl Zeiss semiautomatic microinjector in manual
mode.widespread delivery.
Cell
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Immunofluorescence and Microscopy Ensoli, B., Buonaguro, L., Barillari, G., Fiorelli, V., Gendelman, R.,
Morgan, R.A., Wingfield, P., and Gallo, R.C. (1993). Release, uptake,Cells to be processed for immunofluorescence were washed with
PBS and fixed for 15 min at room temperature with either 100% and effects of extracellular human immunodeficiency virus type 1
Tat protein on cell growth and viral transactivation. J. Virol. 67,methanol for cell permeabilization, or 4% paraformaldehyde in PBS
for cell-surface staining. The samples were then blocked with 10% 277±287.
calf serum in PBS for 15 min at room temperature. Primary antibody Fawell, S., Seery, J., Daikh, Y., Moore, C., Cheng, L.L., Pepinsky,
was added in the same solution and incubated for 20 min at room B., and Barsoum, J. (1994). Tat-mediated delivery of heterologous
temperature. Following 2 3 5 min washes with PBS, secondary proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664±668.
antibodies were added in the blocking solution and incubated for
Forrester, A., Farrell, H., Wilkinson, G., Kaye, J., Davis-Poynter, N.,10 min. Two additional 5 min washes were carried out before the
and Minson, T. (1992). Construction and properties of a mutant ofcoverslips were mounted in glycerol. To stain DNA, propidium iodide
herpes simplex virus type 1 with glycoprotein H coding sequenceswas added to the glycerol mountant at a final concentration of 3
deleted. J. Virol. 66, 341±348.
mg/ml. Samples were examined in dual channels using a Bio-Rad
Fuller, A.O., Santos, R.E., and Spear, P.G. (1989). Neutralizing anti-MRC600 confocal microscope, and images processed using Adobe
bodies specific for glycoprotein H of herpes simplex virus permitPhotoshop software.
attachment to cells but prevent penetration. J. Virol. 63, 3435±3443.
Western Blot Analysis Gompels, U., and Minson, A.C. (1986). The properties and sequence
Proteins were separated by SDS-PAGE, and the gels transferred of glycoprotein H of herpes simplex virus type 1. Virology 153,
to nitrocellulose filters and reacted with the appropriate primary 230±247.
antibody. A horseradish peroxidase±linked secondary conjugate Harlow, E., Crawford, L.V., Pim, D.C., and Williamson, N.M. (1981).
was utilized, and reactive bands visualized using the Enhanced Monoclonal antibodies specific for simian virus 40 tumor antigens.
Chemiluminescence (ECL) Detection Reagents (Amersham). J. Virol. 39, 861±869.
Helland, D.E., Welles, J.L., Caputo, A., and Haseltine, W.A. (1991).
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